Investors sentiment is 0.89 in Q3 2019. Its the same as in 2019Q2. It is without change, as 36 investors sold ABT shares while 592 reduced holdings. only 128 funds opened positions while 434 raised stakes. 1.26 billion shares or 0.10% less from 1.26 billion shares in 2019Q2 were reported. Apg Asset Mngmt Nv reported 0.14% stake. Spinnaker Trust reported 0.41% stake. 4,490 were accumulated by Lawson Kroeker Investment Management Ne. Taurus Asset Limited Liability Corp has invested 0.32% in Abbott Laboratories (NYSE:ABT). Saturna holds 1.04% of its portfolio in Abbott Laboratories (NYSE:ABT) for 429,025 shares. Loring Wolcott And Coolidge Fiduciary Llp Ma has 2.28% invested in Abbott Laboratories (NYSE:ABT) for 1.88M shares. Capital World Investors accumulated 233,125 shares. Mirae Asset Global Invs accumulated 482,152 shares or 0.28% of the stock. Putnam Invs has 1.53 million shares. Bancshares Of Montreal Can accumulated 3.35 million shares. Whittier Tru Company holds 0.77% or 319,814 shares. Texas Yale invested in 0.03% or 5,435 shares. Legal And General Public holds 0.47% of its portfolio in Abbott Laboratories (NYSE:ABT) for 10.62M shares. Moreover, Iowa Natl Bank has 0.84% invested in Abbott Laboratories (NYSE:ABT) for 26,592 shares. Moreover, Proshare Limited Liability Com has 0.63% invested in Abbott Laboratories (NYSE:ABT) for 1.33 million shares.
Rhenman & Partners Asset Management Ab decreased its stake in Abbott Laboratories (ABT) by 15.19% based on its latest 2019Q3 regulatory filing with the SEC. Rhenman & Partners Asset Management Ab sold 39,438 shares as the company’s stock rose 1.50% . The institutional investor held 220,114 shares of the major pharmaceuticals company at the end of 2019Q3, valued at $18.42M, down from 259,552 at the end of the previous reported quarter. Rhenman & Partners Asset Management Ab who had been investing in Abbott Laboratories for a number of months, seems to be less bullish one the $152.00 billion market cap company. The stock increased 0.15% or $0.13 during the last trading session, reaching $86.1. About 761,980 shares traded. Abbott Laboratories (NYSE:ABT) has risen 19.49% since December 13, 2018 and is uptrending. It has outperformed by 19.49% the S&P500.
Rhenman & Partners Asset Management Ab, which manages about $797.70 million US Long portfolio, upped its stake in Alexion Pharmaceuticals Inc (NASDAQ:ALXN) by 44,286 shares to 247,303 shares, valued at $24.22M in 2019Q3, according to the filing. It also increased its holding in Nektar Therapeutics (NASDAQ:NKTR) by 475,000 shares in the quarter, for a total of 1.20 million shares, and has risen its stake in Esperion Therapeutics Inc (NASDAQ:ESPR).
Analysts await Abbott Laboratories (NYSE:ABT) to report earnings on January, 22. They expect $0.95 earnings per share, up 17.28 % or $0.14 from last year’s $0.81 per share. ABT’s profit will be $1.68B for 22.66 P/E if the $0.95 EPS becomes a reality. After $0.84 actual earnings per share reported by Abbott Laboratories for the previous quarter, Wall Street now forecasts 13.10 % EPS growth.
More notable recent Abbott Laboratories (NYSE:ABT) news were published by: Finance.Yahoo.com which released: “Abbott Laboratories (NYSE:ABT) Seems To Use Debt Rather Sparingly – Yahoo Finance” on November 06, 2019, also Finance.Yahoo.com with their article: “Abbott Raises Quarterly Dividend 12.5%, Increasing Payouts for 48 Straight Years – Yahoo Finance” published on December 13, 2019, Fool.com published: “Is Abbott Laboratories Stock a Buy? – The Motley Fool” on December 08, 2019. More interesting news about Abbott Laboratories (NYSE:ABT) were released by: Seekingalpha.com and their article: “Stocks To Watch: Netflix, Cisco And Chewy On The Marquee – Seeking Alpha” published on December 07, 2019 as well as Investorplace.com‘s news article titled: “Best ETFs for 2020: The AdvisorShares Vice ETF Is a Long-Term Winner – Investorplace.com” with publication date: December 11, 2019.
Abbott Laboratories (NYSE:ABT) Ratings Coverage
Among 4 analysts covering Abbott Labs (NYSE:ABT), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Abbott Labs has $9800 highest and $9000 lowest target. $93.75’s average target is 8.89% above currents $86.1 stock price. Abbott Labs had 7 analyst reports since June 21, 2019 according to SRatingsIntel. On Tuesday, July 16 the stock rating was maintained by Morgan Stanley with “Overweight”. The firm earned “Outperform” rating on Thursday, July 18 by BMO Capital Markets. Raymond James maintained the shares of ABT in report on Thursday, July 18 with “Outperform” rating. The rating was maintained by Morgan Stanley with “Buy” on Thursday, October 17. The firm has “Outperform” rating given on Monday, October 14 by Raymond James. Credit Suisse maintained Abbott Laboratories (NYSE:ABT) on Thursday, October 17 with “Outperform” rating.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.